This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 23, 2016
Single-Use System Handles Difficult-to-Mix Ingredients
Author(s)BioPharm International Editors
EMD Millipore’s Mobius Power MIX 2000 can mix buffers, culture media powders, and other challenging materials.
Advertisement
MilliporeSigma's Mobius Power MIX 2000 single-use mixing system effectively handles difficult-to-mix buffers, culture media powders, and other pharmaceutical ingredients. The mixer achieves a strong vortex using an impeller design and motor based on magnetically-coupled NovAseptic technology, a proven mixing technology in stainless steel tanks. The system offers a working volume of 300 to 2000 L for processing flexibility.
The Power MIX 2000 provides accessible, sterile, zero-deadleg sampling directly from the mixing container. A probe port allows for insertion of either a reusable probe for non-aseptic processes or a presterilized, single-use sensor for in-process pH measurement of aseptic processes. Double doors open to one-half the mixer diameter, combined with an off-set drain, to allow easy bag loading. Bags can be loaded by just one person, and an optional integrated hoist is available for powder delivery.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5